James A. Hayman

James A. Hayman

Auto-generated profile, based on publicly available information

James A. Hayman

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2012 in Cancer
Verified
Journal Article
Open access
PDF file
NKNirav S. Kapadia
Nirav S. Kapadia
RMRizvan Mamet
Rizvan Mamet
CZCarrie Zornosa
Carrie Zornosa
JNJoyce C. Niland
Joyce C. Niland
TDThomas A. D'AMico
Thomas A. D'AMico
JHJames A. Hayman
James A. Hayman
BACKGROUND: Receipt of chemotherapy at the end of life (EOL) is considered an indicator of poor quality of care for medical oncology. The objective of this study was to characterize the use of radiotherapy (RT) in patients with nonsmall cell lung cancer (NSCLC) during the same period.METHODS: Treatment characteristics of patients with incurable NSCLC who received RT at the EOL, defined as within 14 days of death, were analyzed from the National Comprehensive Cancer Network NSCLC Outcomes Database.RESULTS: Among 1098 patients who died, 10% had received EOL RT. Patients who did and did not receive EOL RT were similar in terms of sex, race, comorbid disease, and Eastern Cooperative Oncology Group performance status. On multivariable logistic regression analysis, independent predictors of receiving EOL RT included stage IV disease (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.09‐3.83) or multiorgan involvement (OR, 1.75; 95% CI, 1.08‐2.84) at diagnosis, age <65 years at diagnosis (OR, 1.85; 95% CI, 1.21‐2.83), and treating institution (OR, 1.24‐5.94; P = .02). Nearly 50% of EOL RT recipients did not complete it, most commonly because of death or patient preference.CONCLUSIONS: In general, EOL RT was received infrequently, was delivered more commonly to younger patients with more advanced disease, and often was not completed as planned. There also was considerable variation in its use among National Comprehensive Cancer Network institutions. Next steps include expanding this research to other cancers and settings and investigating the clinical benefit of such treatment. Cancer 2012. © 2012 American Cancer Society.

1 December 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RJReshma Jagsi
Reshma Jagsi
KGKent A. Griffith
Kent A. Griffith
FVFrank Vicini
Frank Vicini
TBThomas Boike
Thomas Boike
JBJacob Burmeister
Jacob Burmeister
LPLori J. Pierce
Lori J. Pierce
PURPOSE: Understanding acute toxicities after whole-breast radiotherapy is important to inform patients, guide treatment decisions, and target supportive care. We evaluated patient-reported outcomes prospectively collected from a cohort of patients with breast cancer. METHODS: We describe the maximal toxicity reported by 8,711 patients treated between 2012 and 2019 at 27 practices. Multivariable models identified characteristics associated with (1) breast pain, (2) bother from itching, stinging/burning, swelling, or hurting of the treated breast, and (3) fatigue within 7 days of completing whole-breast radiotherapy. RESULTS: Moderate or severe breast pain was reported by 3,233 (37.1%): 1,282 (28.9%) of those receiving hypofractionation and 1,951 (45.7%) of those receiving conventional fractionation. Frequent bother from at least one breast symptom was reported by 4,424 (50.8%): 1,833 (41.3%) after hypofractionation and 2,591 (60.7%) after conventional fractionation. Severe fatigue was reported by 2,008 (23.1%): 843 (19.0%) after hypofractionation and 1,165 (27.3%) after conventional fractionation. Among patients receiving hypofractionated radiotherapy, younger age ( P < .001), higher body mass index (BMI; P < .001), Black ( P < .001) or other race ( P = .002), smoking status ( P < .001), larger breast volume ( P = .002), lack of chemotherapy receipt ( P = .004), receipt of boost treatment ( P < .001), and treatment at a nonteaching center predicted breast pain. Among patients receiving conventionally fractionated radiotherapy, younger age ( P < .001), higher BMI ( P = .003), Black ( P < .001) or other race ( P = .002), diabetes ( P = .001), smoking status ( P < .001), and larger breast volume ( P < .001) predicted breast pain. CONCLUSION: In this large observational data set, substantial differences existed according to radiotherapy dose fractionation. Race-related differences in pain existed despite controlling for multiple other factors; additional research is needed to understand what drives these differences to target potentially modifiable factors. Intensifying supportive care may be appropriate for subgroups identified as being vulnerable to greater toxicity.

1 August 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
BDBadih J. Daou
Badih J. Daou
GPGregory Palmateer
Gregory Palmateer
BTB. Gregory Thompson
B. Gregory Thompson
CMCormac O. Maher
Cormac O. Maher
JHJames A. Hayman
James A. Hayman
APAditya S. Pandey
Aditya S. Pandey

1 May 2017 in Practical Radiation Oncology
Verified
Journal Article
Closed access
JMJean M. Moran
Jean M. Moran
MFMary Feng
Mary Feng
LBLisa A. Benedetti
Lisa A. Benedetti
RMRobin Marsh
Robin Marsh
KGKent A. Griffith
Kent A. Griffith
LPLori J. Pierce
Lori J. Pierce

1 July 2003 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
MMMichele Melia
Michele Melia
CMClaudia S Moy
Claudia S Moy
SRSandra M Reynolds
Sandra M Reynolds
DCDavid Cella
David Cella
TMTimothy G. G. Murray
Timothy G. G. Murray
CGCollaborative Ocular Melanoma Study-Quality Of Life Study Group
Collaborative Ocular Melanoma Study-Quality Of Life Study Group
Research from JAMA Ophthalmology — Development and Validation of Disease-Specific Measures for Choroidal Melanoma — COMS-QOLS Report No. 2

19 November 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
BDB.J. Daou
B.J. Daou
GPG. Palmateer
G. Palmateer
DWD.A. Wilkinson
D.A. Wilkinson
BTB.G. Thompson
B.G. Thompson
CMC.O. Maher
C.O. Maher
APA.S. Pandey
A.S. Pandey
BACKGROUND AND PURPOSE: T2 signal and FLAIR changes in patients undergoing stereotactic radiosurgery for brain AVMs may occur posttreatment and could result in adverse radiation effects. We aimed to evaluate outcomes in patients with these imaging changes, the frequency and degree of this response, and factors associated with it. MATERIALS AND METHODS: Through this retrospective cohort study, consecutive patients treated with stereotactic radiosurgery for brain AVMs who had at least 1 year of follow-up MR imaging were identified. Logistic regression analysis was used to evaluate predictors of outcomes. RESULTS: One-hundred-sixty AVMs were treated in 148 patients (mean, 35.6 years of age), including 42 (26.2%) pediatric AVMs. The mean MR imaging follow-up was 56.5 months. The median Spetzler-Martin grade was III. The mean maximal AVM diameter was 2.8 cm, and the mean AVM target volume was 7.4 mL. The median radiation dose was 16.5 Gy. New T2 signal and FLAIR hyperintensity were noted in 40% of AVMs. T2 FLAIR volumes at 3, 6, 12, 18, and 24 months were, respectively, 4.04, 55.47, 56.42, 48.06, and 29.38 mL Radiation-induced neurologic symptoms were encountered in 34.4%. In patients with radiation-induced imaging changes, 69.2% had new neurologic symptoms versus 9.5% of patients with no imaging changes (P = .0001). Imaging changes were significantly associated with new neurologic findings (P < .001). Larger AVM maximal diameter (P = .04) and the presence of multiple feeding arteries (P = .01) were associated with radiation-induced imaging changes. CONCLUSIONS: Radiation-induced imaging changes are common following linear particle accelerator–based stereotactic radiosurgery for brain AVMs, appear to peak at 12 months, and are significantly associated with new neurologic findings.